Harrow, Inc. Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)
Harrow, Inc. (HROW) had Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) of $750.00 thousand as of 2012-04-20, per its 10-K filed 2014-03-28.
Discontinued › Notes
us-gaap:LineOfCreditFacilityAmountOutstanding · last filed 2014-03-28
- 2012-04-20: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $750.00K.
| Period end | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) |
|---|---|
| 2012-04-20 | $750.00K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |